PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2073463
PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2073463
According to Mordor Intelligence, the japan ophthalmic devices market size is expected to grow from USD 2.44 billion in 2025 to USD 2.62 billion in 2026 and is forecast to reach USD 3.72 billion by 2031 at 7.28% CAGR over 2026-2031.

This report is Segmented by Device Type (Diagnostic & Monitoring Devices, Surgical Devices, and Vision Care Devices), Disease Indication (Cataract, Glaucoma, Diabetic Retinopathy, Other Disease Indications), End-User (Hospitals, Specialty Ophthalmic Clinics, and More). The Market Forecasts are Provided in Terms of Value (USD).
An unprecedented demographic shift places nearly 30% of Japan's citizens above 65, triggering consistent cataract surgery demand that reached 1.6 million procedures in 2019 and continues to climb in 2025. Hospital audits show a growing share of patients over 90 benefiting from modern phacoemulsification combined with premium intraocular lenses, with documented cognitive score gains from 25.65 to 27.08 on the MMSE after surgery. This broader health impact positions cataract care as more than a vision solution and amplifies purchaser willingness to pay for femtosecond laser platforms, toric lens calculators, and digitally assisted microscopes. Manufacturers bundle ergonomic handpieces and workflow software to sustain throughput amid a tightening surgical workforce. Over the long run, this driver is expected to lift the Japan ophthalmic devices market by 2.0 percentage points of cumulative CAGR.
Japanese myopia rates among children aged 6-14 rose from 10% in the late 1970s to 53% by 2010 and remain above 36% in 2025, with COVID-19-related indoor lifestyles worsening the trend. The scale of the issue prompted Santen to launch RYJUSEA Mini (atropine 0.025%) in April 2025, the first locally approved therapy to slow myopia progression. Uptake of axial-length measurement devices, auto-refractors with cycloplegic modes, and school-based screening kiosks is accelerating. Vision-care market leaders promote spectacle lenses such as MiYOSMART and daily disposable contact lenses through omnichannel campaigns targeting concerned parents. These developments collectively could add 1.3 percentage points to the sector's growth trajectory through 2030.
Femtosecond laser units, multimodal microscopes, and robotic cataract platforms require upfront payments topping USD 350,000, locking out clinics that handle fewer than 18 cases per week. While leading chains in Tokyo and Osaka easily secure financing, smaller providers face thin margins because reimbursement rates have not risen in line with device precision upgrades. Leasing and pay-per-procedure contracts now appear in tender documents, yet interest rates above 2% add further strain. As a result, the addressable pool of purchasers narrows, trimming 1.8 percentage points from the five-year growth outlook of the Japan ophthalmic devices market.
Other drivers and restraints analyzed in the detailed report include:
For complete list of drivers and restraints, kindly check the Table Of Contents.
Vision-care platforms accounted for 64.78% of 2025 revenue, reflecting the nation's long-standing reliance on corrective eyewear. HOYA's channel audits show contact-lens penetration expanding at 2% per year, with bifocal and myopia-control options fueling basket size gains. Diagnostic and monitoring equipment is the fastest riser, set to log a 9.58% CAGR through 2031 as self-imaging OCT, swept-source devices, and AI-ready fundus scanners move from tertiary centers into primary clinics. Adoption of Canon's OCT-R1, which earned a Red Dot award for its compact footprint, exemplifies this pivot toward earlier detection. Across both tiers, value-added software subscriptions help offset fee-schedule pressure by bundling analytics dashboards and remote consultation features into hardware sales. These multi-modal strategies underpin sustained leadership for platform vendors while widening access to proactive eye-health management.
Growth momentum in surgical devices remains steady, underpinned by minimally invasive glaucoma stents, single-use vitrectomy cutters, and compact phaco consoles designed for ASC workflows. Femtosecond laser cataract systems deliver added precision, yet their high capital requirement restricts uptake to high-volume metropolitan centers. To narrow this affordability gap, manufacturers trial pay-per-click models that align unit economics with procedure counts in tier-2 clinics. As a result, the Japan ophthalmic devices market size attributed to surgical technology is expected to expand but at a more measured pace than diagnostics.